4basebio launches high-capacity single-stranded DNA product line

(Sharecast News) - 4basebio said on Monday that it had commercially launched a high-capacity single-stranded DNA product line aimed at supporting the development of gene editing, cell engineering and nucleic acid-based medicines.

The AIM-traded synthetic DNA manufacturer said the platform was built on its proprietary enzymatic manufacturing process and was designed to produce high-purity, long-form, ends-protected ssDNA templates for CRISPR-based gene editing and other therapeutic applications.

It said the platform was intended to address manufacturing and performance limitations associated with traditional chemical synthesis, particularly for complex knock-in applications where demand for longer and purer DNA templates had increased.

4basebio said its ssDNA offering could produce constructs of up to 10,000 nucleotides with protected ends, providing stability, reduced immunogenicity and a clearer route towards clinical manufacturing.

The company said the technical advantages of the platform would be presented at the American Society of Gene & Cell Therapy annual meeting in Boston, where Amine Bouchareb, its director of molecular biology and gene editing, would give a presentation on 14 May.

Chief executive Amy Walker said the launch marked "a pivotal milestone" in the company's aim to provide tools for genomic medicine and personalised therapies.

"By replacing legacy chemical synthesis with our scalable, cell-free enzymatic approach, we are empowering our partners to design therapies without the traditional constraints of length or sequence complexity," she said.

"We are not just providing DNA; we are enhancing the reliability and safety profile required for life-changing therapeutics."

Bouchareb said researchers had previously faced a trade-off between the toxicity of double-stranded DNA and the length limits of chemically synthesised oligonucleotides.

"Our enzymatic platform eliminates this compromise," he said.

"At ASGCT, I look forward to presenting data that demonstrates how our long-form ssDNA constructs significantly enhance Homology Directed Repair gene editing efficiency while maintaining superior cell viability in sensitive primary cell types."

At 0817 BST, shares in 4basebio were up 0.59% at 457.7p.

Reporting by Josh White for Sharecast.com.

See latest RNS on Investegate

4basebio Plc